Home Biosimilar Antibodies Immunology & Inflammation CD markers Inotuzumab (Anti-Siglec-2 / CD22)
For research use only. Not for use in humans.

Inotuzumab (Anti-Siglec-2 / CD22)

Synonyms: Siglec-2， BL-CAM

Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD.

Inotuzumab (Anti-Siglec-2 / CD22)

Quality Control

Batch: A235801 Purity: 99% Protein concentration: 6.7mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD.

Product Details

CAS No. 1660159-36-3
Molecular Weight 144.78 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06343090 RECRUITING Drug: CD19 CAR T-cell|Drug: CD22 CAR T cells B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoid Leukemia Beijing GoBroad Hospital 2024-04-12
NCT02650414 ACTIVE_NOT_RECRUITING B Cell Leukemias; B Cell Lymphomas University of Pennsylvania 2016-01-13 PHASE1
NCT04815356 RECRUITING Hairy Cell Leukemia; Hairy Cell Leukemia Variant National Cancer Institute (NCI) 2022-05-23 PHASE1
NCT03620058 ACTIVE_NOT_RECRUITING Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia University of Pennsylvania 2018-09-27 PHASE1
NCT04307576 RECRUITING Drug: Omitted Doxorubicin|Drug: Omitted Vincristine+Dexameth Leukemia, Acute Lymphoblastic Mats Heyman 2020-07-13 PHASE3
NCT05748171 RECRUITING Drug: Inotuzumab ozogamicin|Drug: ALLR3 ACUTE LYMPHOBLASTIC LEUKEMIA Pfizer 2023-05-17 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-10)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.